Search Results
Apr 13, 2026, 08:09 ET Iterion Presents New Data on First-in-Class TBL1 Inhibitor Tegavivint, Targeting Wnt-Driven Cancers at AACR Annual Meeting
where Wnt signaling drives disease."Iterion recently completed a Phase 1 study of tegavivint in patients with advanced hepatocellular carcinoma (HCC), where the therapy demonstrated encouraging clinical responses and durable disease control in heavily pre-treated patients, along with a favorable tolerability
More news about: Iterion Therapeutics
Apr 09, 2026, 20:00 ET Oricell Therapeutics Closes $110 Million Pre-IPO Financing to Accelerate Global Development of Solid Tumor CAR-T Therapies
vanguard of the global CAR-T race.OriCell's lead asset, Ori-C101, is a GPC3-targeted autologous CAR-T therapy for advanced hepatocellular carcinoma (HCC). Having successfully navigated investigator-initiated trials (IIT) and a registrational Phase 1 study, the program is now gearing up for pivotal trials.
More news about: Oricell Therapeutics Holdings Limited
Apr 08, 2026, 07:00 ET Blue Faery Honors Dr. Richard Finn and Dr. R. Kate Kelley for Transformative Contributions to Liver Cancer Care
Adrienne Wilson's birthday. Had she survived liver cancer, she would have turned 40 this year.Honoring Leadership and Lasting Impact in HCCDrs. Finn and Kelley are widely recognized for advancing the care of hepatocellular carcinoma through leadership in research, clinical trials,
More news about: Blue Faery: The Adrienne Wilson Liver Cancer Association
Apr 07, 2026, 08:05 ET PENGUIN AI LAUNCHES PRIOR AUTHORIZATION AND MEDICAL CODING SOLUTIONS AS SNOWFLAKE NATIVE APPS ON SNOWFLAKE MARKETPLACE
organizations. Purpose-built with domain-specific reasoning, agentic automation, and transparent auditability, Penguin Ai accelerates prior authorization, HCC coding and risk adjustment, claims adjudication, payment integrity, appeals, and other mission-critical processes. Penguin Ai integrates seamlessly with
More news about: Penguin Ai
Apr 07, 2026, 08:00 ET Reveleer Introduces Clinical Data Repository to Establish a Unified, AI-Enriched Member-Level Clinical Record Across Health Plan Enterprise Operations
demonstrate the evidentiary basis for their coding and quality submissions over multiple years.A single member-level clinical record supports HCC coding, Stars and HEDIS performance,
More news about: Reveleer
Apr 06, 2026, 23:28 ET Akeso Presents Updated Data on Cadonilimab Combination Therapy in PD-(L)1 Inhibitor-Resistant Advanced NSCLC at ELCC 2026
regimens have previously shown promising therapeutic potential in difficult-to-treat tumors, including immunotherapy-refractory hepatocellular carcinoma (HCC) and gastric cancer. The updated data presented at ELCC 2026 now provide further robust evidence of cadonilimab's important additional value in treating
More news about: Akeso, Inc.
Apr 05, 2026, 16:51 ET TTW Reveals Top 100 Convention Centers in the World for 2026
industrial economy while enabling large-scale conferences, exhibitions, and corporate gatherings in central Japan.32. Hawaii Convention Center (HCC), Honolulu, United StatesThe Hawaii Convention Center stands out for its unique open-air architectural design, blending modern infrastructure
More news about: Travel And Tour World
Apr 01, 2026, 08:05 ET Penguin Ai Launches Gwen, a Build-Your-Own AI Platform for Healthcare Operations
Gwen ships with a library of more than 100 pre-built clinical digital workers covering HCC retrospective coding, prior authorization intake, clinical documentation summarization and eligibility verification. Teams that need a workflow beyond
More news about: Penguin Ai
Mar 31, 2026, 22:02 ET Abbisko Therapeutics' FGFR4 Inhibitor Irpagratinib Granted Orphan Drug Designation by EMA for Hepatocellular Carcinoma
cause of cancer-related mortality worldwide, with HCC accounting for approximately 75%–85% of cases. Currently, immune checkpoint inhibitors (ICIs) combined with anti-angiogenic therapy have become the standard first-line treatment for advanced HCC. However, effective second-line and later-line options
More news about: Abbisko
Mar 31, 2026, 09:15 ET ABK Biomedical and MURR Forge Long-Term Partnership to Advance Breakthrough Cancer Therapy
driven critical progress in Eye90 development and is fueling the recently-fully-enrolled Route90 FDA IDE clinical trial for hepatocellular carcinoma (HCC). By formalizing this continuing alliance, ABK secures a reliable and scalable production partner for Eye90 microspheres and brings life-saving treatments
More news about: ABK Biomedical Inc.
Mar 30, 2026, 09:53 ET Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth
well as in combination trials with PD-1 inhibitors for melanoma, colorectal cancer (CRC), neuroendocrine neoplasm (NEN) and hepatocellular carcinoma (HCC).In October 2025, the Company published positive Phase II clinical data in combination with tislelizumab, for the treatment of microsatellite
More news about: Harbour BioMed
Mar 26, 2026, 23:54 ET Akeso Reports Full-Year 2025 Financial Results
a head-to-head Phase III trial against nivolumab in first line gastric cancer, and a registrational trial for IO-resistant hepatocellular carcinoma (HCC). These high-efficiency global studies aim to address significant unmet medical needs, further unlocking cadonilimab's global therapeutic value.
More news about: Akeso, Inc.
Mar 26, 2026, 09:32 ET CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0
esophageal squamous cell carcinoma (ESCC), platinum-resistant ovarian cancer (PROC), triple-negative breast cancer (TNBC), and hepatocellular carcinoma (HCC). Active patient enrollment is ongoing in Australia and China.First-in-class (FIC)/best-in-class (BIC) potential as next-generation
More news about: CStone Pharmaceuticals
Mar 26, 2026, 08:53 ET CStone Updated Clinical Progress and Key Phase I/II Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)
esophageal squamous cell carcinoma (ESCC), platinum-resistant ovarian cancer (PROC), triple-negative breast cancer (TNBC), and hepatocellular carcinoma (HCC).1. Monotherapy Shows Striking Efficacy in First-line NSCLC:CS2009 monotherapy (20 mg/30 mg, Q3W) achieved an ORR of 90% (9/10)
More news about: CStone Pharmaceuticals
Mar 18, 2026, 08:42 ET Helio Genomics to Make HelioLiver™ Cancer Test Accessible to Quest Diagnostics' Providers
blood-based early detection test for Hepatocellular Carcinoma (HCC), widely available to physicians and patients through Quest's extensive U.S. network. The test aims to help power earlier intervention in patients who are at risk of developing HCC, the most common primary liver cancer. Starting in April,
More news about: Helio Genomics
Mar 12, 2026, 07:45 ET Singular Genomics Names the Spatial Technologies Unit at Beth Israel Deaconess Medical Center a G4X™ Center of Excellence
announced that the Spatial Technologies Unit (STU) at Beth Israel Deaconess Medical Center (BIDMC), a Dana-Farber/Harvard Cancer Center (DF/HCC) Core Facility, has been designated a G4X™ Center of Excellence.
More news about: Singular Genomics
Mar 09, 2026, 02:28 ET Leads Biolabs' Opamtistomig (LBL-024) Enrolls First ESCC Patient, Exploring Dual PD-L1/4-1BB Mechanism for Superior Survival Benefits in China's High-Incidence Cancer
biliary tract cancer (BTC), ovarian cancer (OC), non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), hepatocellular carcinoma (HCC), gastric cancer (GC), triple-negative breast cancer (TNBC), and malignant melanoma. Encouraging clinical activity has already been observed in NSCLC,
More news about: Leads Biolabs
Mar 05, 2026, 17:00 ET AES Announces Launch of Consent Solicitation for Senior Notes
"2030 Notes")00130HCC7U0080RAR1$700,000,000
More news about: The AES Corporation
Mar 03, 2026, 20:37 ET Specialty Insurance Market to Grow at 9.7% CAGR by 2031 Supported by Expansion in Livestock and Aquaculture Insurance, Says Mordor Intelligence
GroupAXA SAAllianz SEChubb LtdBerkshire Hathaway SpecialtyMunich Re Specialty GroupTokio Marine HCCZurich Insurance GroupGenerali Global Corporate & SpecialtyPICCMapfre SASompo InternationalFairfax
More news about: Mordor Intelligence Private Limited
Feb 25, 2026, 11:00 ET REGAL MEDICAL GROUP ANNOUNCES OPENING OF NEW REGAL WELLNESS CENTER IN BEAUMONT
practices," said Jasmine Frank, Senior Vice President of Regional Operations at Regal Medical Group. "They reduce administrative burden, improve accuracy in HCC documentation and RAF performance, and enhance the overall patient experience—while maintaining strong coordination with physicians and health plan partners."The
More news about: Regal Medical Group
Feb 24, 2026, 19:30 ET Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)
achieved an ORR of 58.1% and a DCR of 87.1%. Clinical activity has also been observed in additional tumor types, including hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC), supporting the potential of PD-1/VEGF dual targeting across multiple tumor settings. To date, JS207 has 11 ongoing
More news about: Antengene Corporation Limited
Feb 24, 2026, 09:15 ET ABK Biomedical Completes Enrollment in ROUTE90 Pivotal Study for Primary Liver Cancer
Final Patient Treated in FDA IDE Study Evaluating Eye90 microspheres® for the Treatment of Unresectable Hepatocellular Carcinoma (HCC)HALIFAX, NS, Feb. 24, 2026 /PRNewswire/ - ABK Biomedical, Inc., an innovative,
More news about: ABK Biomedical Inc.
Feb 15, 2026, 19:10 ET CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial
combination therapy cohorts across 9 solid tumor indications, including NSCLC, CRC, TNBC, ES-SCLC, PROC, cervical cancer (CC), hepatocellular carcinoma (HCC), gastric or gastroesophageal junction cancer (GC/GEJC), and esophageal squamous cell carcinoma (ESCC). The trial is actively enrolling patients in Australia
More news about: CStone Pharmaceuticals
Feb 12, 2026, 09:00 ET WellLink and The Healthcare Council Announce Strategic Affiliation to Expand Regional and National Impact
Lane providing executive leadership, while ensuring continuity for members, partners, and staff. Both associations, WellLink and The Healthcare Council (HCC), will continue operating under their existing brands. Customers of HCC's group purchasing organizations (GPO), ShareSource and Purchasing Connections,
More news about: WellLink
Feb 11, 2026, 09:05 ET Medicomp Systems Unveils New AI-Enablement Tools Focused on Delivering Clinically Validated, Evidence-Based Intelligence
including diagnostic prompting, documentation tools, quality measure and care gap evaluation, coding crosswalks, chart summarization, graphing tools, and HCC and RAF analysis, as well as
More news about: Medicomp Systems